Mounjaro and Zepbound brought in about $16.1 billion for Lilly in Q3

More peptides

1. GLP-1 obesity drug sales value rose 72% in September 2026 as units fell 10%

   FFacebook Oct 30

   peptides typeshitPrices

   GLP-1 obesity drug sales value rose 72% in September 2026 as units fell 10%

   New generics and steady prices drove the jump in sales value, with Eli Lilly's tirzepatide leading the market.

   See it on Facebook
2. UBS lifts its Eli Lilly price target to $1,625 on obesity drug demand

   YFYahoo Finance Oct 30

   peptides typeshitPrices

   UBS lifts its Eli Lilly price target to $1,625 on obesity drug demand

   UBS says volumes grew about 55% while net prices fell roughly 14%, and points to about 500,000 people joining Lilly's Medicare bridge program in a few months.

   Read at Yahoo Finance
3. Weight loss market forecast to reach $244 billion by 2036, led by GLP-1 drugs

   YFYahoo Finance Oct 30

   peptides typeshitPrices

   Weight loss market forecast to reach $244 billion by 2036, led by GLP-1 drugs

   A new market report values the sector at $97.5 billion in 2025 and expects oral and multi-pathway drugs to grow fastest as Medicare coverage starts in mid-2026.

   Read at Yahoo Finance
4. Forbes breaks down prices for semaglutide, tirzepatide and compounded GLP-1s

   FForbes Oct 30

   peptides typeshitPrices

   Forbes breaks down prices for semaglutide, tirzepatide and compounded GLP-1s

   Forbes compares what brand-name semaglutide and tirzepatide cost against compounded GLP-1 versions.

   Read at Forbes
5. Facebook share says retatrutide doubled the weight loss of Ozempic's top dose

   FFacebook Oct 30

   peptides typeshitResearch

   Facebook share says retatrutide doubled the weight loss of Ozempic's top dose

   A short repost of Eli Lilly trial results, crediting retatrutide with more than twice the weight loss of Ozempic's highest dose.

   See it on Facebook
6. GLP-1 use around surgery tied to fewer heart events and infections in a large study

   MMPR Oct 30

   peptides typeshitResearch

   GLP-1 use around surgery tied to fewer heart events and infections in a large study

   In 2 million surgical patients, GLP-1 users had slightly lower odds of complications. UTHealth's Josephine Tolan says more research is needed on cause.

   Read at MPR